Peptides: Promising Doesn't Mean Proven

Peptides attract attention for understandable reasons. Their roles in biological signalling offer interesting possibilities, and early research can suggest new approaches to difficult health problems.

But an exciting possibility and an established treatment occupy different places in clinical care.

My approach is to remain curious while being precise about what the evidence actually demonstrates.

First, peptides are not one treatment category with one evidence rating.

Some peptide medicines have established clinical uses supported by human trials. Other peptides remain experimental, with evidence largely drawn from laboratory or animal studies.

The word “peptide” tells us something about a molecule’s structure. It does not tell us whether that molecule works for a particular condition, which dose is appropriate, or whether its benefits outweigh its risks.

Those questions require evidence about the specific intervention and its intended use.

A mechanism is a starting point.

A study might show that a peptide changes inflammatory signalling, influences collagen production or improves a measure of mitochondrial function.

These findings can help explain why researchers want to investigate it further. They do not establish that a person will experience less pain, recover faster or avoid disease progression.

The next question is whether the proposed biological effect translates into a meaningful human benefit.

Animal research deserves attention—and accurate labelling.

An improvement in a mouse model can be valuable. It helps researchers explore mechanisms and decide which candidates deserve further study.

However, experimental injuries and diseases do not reproduce every feature of human illness. Differences in metabolism, administration and dose also complicate translation.

An animal finding should be described as an animal finding, even when its implications are promising.

Human research also needs careful examination.

A small uncontrolled study can identify an interesting signal. It cannot reliably separate treatment effects from natural recovery, concurrent care or expectations.

I look at who participated, what they received, whether there was a suitable comparison group, and which outcomes were measured.

I also ask whether the findings have been independently replicated and whether follow-up was long enough to assess benefit and harm.

The product matters as much as the name.

Evidence from a defined research preparation does not automatically apply to a product sold online under the same name.

Identity, purity, sterility and consistency are separate questions from biological plausibility. A study cannot establish the quality of an unrelated vial.

Uncertainty should remain visible.

“Promising” can be an accurate and useful description. It becomes misleading when it quietly turns into “proven,” “safe” or “regenerative” without the necessary evidence.

My philosophy is to give emerging research room to develop while keeping established care, meaningful outcomes and honest explanations at the centre of clinical decisions.

Curiosity opens the discussion. Evidence determines how confidently we can proceed.

Dr D. Michael Elliott MSc DC CFMP